23-Sep-2019 | Zion Market Research
Zion Market Research has published a new report titled “Overactive Bladder Treatment Market By Pharmacotherapy (Anticholinergic, Botox, and Others) and By Disease (Neurogenic Overactive Bladder and Idiopathic Overactive Bladder): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global overactive bladder treatment market was USD 3,731 million in 2018 and is expected to generate around USD 4,594 million by 2025, at a CAGR of around 3% between 2019 and 2025.
Overactive bladder is a urological condition associated with urination problems and is also known as overactive bladder syndrome. Major symptoms include urgency in urination and change in urination frequency. It can cause various neurological diseases, such as Parkinson’s disease. Overactive bladder can affect anyone, irrespective of one’s age and gender. Growing prevalence of overactive bladder, escalating geriatric population, and rising neurological disorders are driving the overactive bladder treatment market. Increasing incidences of Parkinson’s disease, overactive bladder in the spinal cord, rising disposable income, growing awareness regarding overactive bladder syndrome, and accelerating technological advancements for patient handling will further boost this market. Moreover, flourishing healthcare infrastructure, increasing government initiatives, and a growing number of doctor worldwide, developing innovative intravesical therapies, and active marketing activities by pharmaceutical giants are some other drivers stimulating the overactive bladder treatment market. However, the lack of awareness and adverse side-effects of current treatments may hinder this market.
Browse the full “Overactive Bladder Treatment Market By Pharmacotherapy (Anticholinergic, Botox, and Others) and By Disease (Neurogenic Overactive Bladder and Idiopathic Overactive Bladder): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/overactive-bladder-treatment-market
The overactive bladder treatment market is segmented on the basis of pharmacotherapy into botox, anticholinergic, and others. The anticholinergic segment dominated the market in 2018, due to solifenacin drug that had a huge demand in 2018. Increase in healthcare infrastructural developments, rise in healthcare expenditure, development of private healthcare facilities, and growth in overactive bladder prevalence are driving this segment. Additionally, escalating rates of smoking, obesity, and consumption of carbonated drinks are also responsible for overactive bladder syndrome.
On the basis of disease, the market includes neurogenic overactive bladder and idiopathic overactive bladder. Neurogenic overactive bladder is further divided into the overactive bladder in stroke, Parkinson’s disease, overactive bladder in multiple sclerosis, overactive bladder in the spinal cord, and overactive bladder in other disorders. Neurogenic overactive bladder accounted for a major market share in 2018, due to the rising prevalence of spinal cord injuries, Parkinson’s disease, and spinal surgeries and increasing per capita income of people in developed and developing countries.
North America dominated the overactive bladder treatment market in 2018 globally. About 11% of the total North American population suffered from overactive bladder complications in 2017. It accounted for 48% of the market share in terms of revenue. Growing prevalence of overactive bladders due to rising geriatric population, increasing diabetic patients, and rising acute urinary tract infection are contributing to the North American market. Europe held the second spot in the overactive bladder treatment market globally in 2018, due to the growing technological advancements and consistently developing hospital infrastructure. The Asia Pacific is expected to account for the fastest growth rate in the overactive bladder treatment market, owing to the huge population in China, India, and Japan.
Some major players involved in the overactive bladder treatment market are Macleods Pharmaceuticals, Allergan, Mylan, Endo International, Sanofi, Apotex, Johnson & Johnson, Aurobindo Pharma, Medtronic, Cogentix Medical, Astellas Pharma, Pfizer, Teva Pharmaceutical, Hisamitsu Pharmaceutical, and Intas Pharmaceuticals.
This report segments the global overactive bladder treatment market into:
Global Overactive Bladder Treatment Market: Pharmacotherapy Analysis
Global Overactive Bladder Treatment Market: Disease Analysis
Global Overactive Bladder Treatment Market: Regional Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651